基底性尿作为利尿剂耐药性和急性心力衰竭的临床演变的预测因素
Cristhian E Scatularo1, Luciano Battioni2, Analía Guazzone1
1Department of Cardiology, Sanatorio de la Trinidad Palermo, Buenos Aires, Argentina.
Current problems in cardiology
|May 25, 2024
概括
在急性心力衰竭 (AHF) 患者中,单次基底性水 (BN) 测量可以预测尿剂耐药性 (DR). 低BN表明较高风险的糟糕的结果和需要密集治疗.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學.
- 临床医学 临床医学
背景情况:
- 临床指导方针建议进行序列性尿测量,以检测急性心力衰竭 (AHF) 患者的尿素耐药性 (DR).
- 这种方法增加了患者管理的复杂性.
研究的目的:
- 为了与住院AHF患者的DR发展和临床结果相关联,在入院时测量单个基底性自然化 (BN).
- 为了简化对AHF的利尿反应的评估.
主要方法:
- 住院AHF患者的前性多中心研究 (不包括冲击或肌素>2.5mg%).
- 患者在入院时接受了静脉注射的罗西米德 (40mg),随后进行了BN测量.
- 利尿剂治疗是以协议为指导的;低BN被定义为<70 meq/L. 药物治疗包括furosemide>240mg/day,管状阻塞 (TB),高血压盐溶液 (HSS) 或置换疗法 (RRT).
主要成果:
- 包括157名患者;22%的人患有低BN. 在19%的患者中发展了DR.
- 较低的BN显着与DR (44%与12%相比),持久性拥堵 (26.5%与11.4%相比),更高的富罗塞米德剂量,结核病,RRT,AHF恶化以及增加住院心血管死亡率有关.
- 低BN也与需要呼吸辅助相关.
结论:
- 单个基底性尿素测量是一种有价值的工具,用于预测AHF的尿剂耐药性.
- 低基底性尿与持续的拥堵有关,增加了对积极的脱策略的需求,以及较差的住院结果.
- 这一发现简化了DR评估,并指导了AHF管理.
更多相关视频
08:505/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
Published on: July 3, 2013
23.6K
07:49Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
1.3K
相关概念视频
01:22Heart Failure Drugs: Diuretics
363
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
363
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
421
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
01:16Antihypertensive Drugs: Action of Diuretics
670
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
670
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
521
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
521
01:22Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K